Compare Amylx Pharmaceuticals Inc (AMLX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Wipro Limited — how do they compare? Amylx Pharmaceuticals Inc trades at $17.17 (market cap $1.98B), while Wipro Limited trades at $1.91 (market cap $18.38B). The key difference: Wipro Limited is far larger — about 9.3× Amylx Pharmaceuticals Inc's market cap, and Wipro Limited pays a 10.25% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | WIT | |
|---|---|---|
Market Cap | $1.98B | $18.38B |
Sector | Health | Technology |
52-Week High | $18.70 | $3.06 |
52-Week Low | $7.64 | $1.82 |
Enterprise Value | $1.70B | $14.77B |
Dividend Yield | — | 10.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
WIT trades at $1.87, up 1.08% today, but faces bearish technical signals with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. Fundamentals show solid profitability with a 14.25% net margin and 15.4% ROE, while valuation metrics like a P/E of 14.05 appear reasonable. Recent news highlights AI partnerships with ServiceNow and Anthropic, though weak Q2 2026 guidance has pressured sentiment.
The outlook is cautious with mixed analyst ratings (19% buy, 48% hold, 33% sell) and near-term revenue headwinds. Investment opportunities lie in AI-driven growth initiatives, but risks include execution challenges and competitive pressures in the IT services sector. Cash flow remains strong at $25.02B net for 2025, supporting financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
